---
schema_version: "secwatch.filing_event.v1"
accession: "0001649094-26-000015"
form_type: "8-K"
ticker: "PCVX"
cik: "0001649094"
company_name: "Vaxcyte, Inc."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:46:15.243894+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vaxcyte Q1 net loss $320.6M; OPUS Phase 3 enrollment completed; topline data Q4 2026

## Summary
- Cash $2.74B as of Mar 31, up from $2.44B Dec 31; includes $601.8M from Feb 2026 equity offering.
- Net loss $320.6M for Q1 2026 vs $140.7M in Q1 2025; R&D expenses doubled to $312.8M.
- All three VAX-31 adult Phase 3 trials (OPUS-1, OPUS-2, OPUS-3) fully enrolled with 6,191 adults dosed.
- Topline OPUS-1 data expected Q4 2026; OPUS-2 and OPUS-3 data expected H1 2027.
- VAX-31 infant Phase 2 fully enrolled (900 infants); topline data by end of H1 2027; VAX-A1 Phase 1 start mid-2026.

## SEC filing metadata
- accession: 0001649094-26-000015
- form_type: 8-K
- ticker: PCVX
- cik: 0001649094
- company_name: Vaxcyte, Inc.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649094/000164909426000015/0001649094-26-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649094/000164909426000015/pcvx-20260506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001649094-26-000015
- JSON: https://secwatch.observer/filing/0001649094-26-000015.json
- Plain text: https://secwatch.observer/filing/0001649094-26-000015.txt

## Source-grounded claims
- claim_id: dd91af0ad21e7ca41a0c22cbcf620da241950346
  claim: Vaxcyte, Inc. reported financial results for the first quarter ended March 31, 2026.
  evidence_excerpt: On May 6, 2026, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649094/000164909426000015/0001649094-26-000015-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.